Bevan lab


Group lead
Prof Charlotte Bevan
+44 (0)20 7594 2135
Twitter: @BevanLab

Related themes

Disease areas

What we do

Prostate tumour growth is, at least initially, dependent on androgens. Treatment for inoperable disease therefore involves removing circulating androgens and opposing their action using antiandrogens. This is effective initially, but many patients relapse with potentially lethal, metastic "castrate-resistant" disease. Understanding the molecular events that lead to therapy resistance is vital for new therapies to be developed.

Why it is important

Prostate cancer is the second most common cause of male cancer deaths. Currently over 40,000 men in the UK are diagnosed with prostate cancer each year. Our aims are to investigate mechanisms of prostate cancer development and progression, with emphasis on research leading to the development of new therapies or improvement in the application of existing therapies.

How it can benefit patients

Prostate cancer prognosis varies widely – some tumours are never life-threatening while others develop rapidly into lethal disease. Given the severity of side-effects of many drugs and the variation in response, it is important that patients and clinicians can make informed choices about which therapy to us. To facilitate this we are identifying appropriate biomarkers to stratify prostate tumours upon diagnosis, and models to identify potential side effects, as well as novel therapies.

Summary of current research

  • Evaluating androgen action in prostate cancer progression and therapy
  • Exploiting non-coding RNAs as therapeutic targets and stratification biomarkers in therapy-resistant prostate cancer
  • MicroRNA drivers of therapy resistance in Prostate Cancer
  • Engineering Novel Repressors for the Treatment of Prostate Cancer
  • Nuclear receptor signalling pathways in stratification and therapy for prostate cancer
  • A high-throughput and minimally invasive approach for diagnosis and prognosis of Cancer


Public engagement





For patients

  • Prostate Cancer UK - For information on prostate cancer, helplines manned by trained professionals as well as links to support groups and an online community
  • Cancer Research UK for statistics, information and support

PhD students

When we have funding for PhD studentships, we advertise them through central channels such as Find a PhD. Information is also available on the Surgery and Cancer study page. If no studentships are currently advertised, please get in touch with the group lead with proposed project titles to discuss further. 

Current PhD students:

  • Ieva Eringyte, PCF student. MicroRNA drivers of drug resistance in prostate cancer
  • Flavia I Fioretti, PCUK student. Engineered repressors of androgen signalling as a novel therapeutic strategy for advanced prostate cancer
  • Foteini Kalofonou. Androgen signalling-modulating microRNAs in prostate cancer progression and therapy
  • Akifumi Shibakawa, Movember/PCUK student
  • Sharmila Rana (with Hector Keun), PCUK student. MicroRNA networks in prostate cancer


Our researchers

Dr Gilberto Serrano de Almeida

Image Description

Dr Gilberto Serrano de Almeida
Research Associate